Results 161 to 170 of about 41,075 (183)

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Lancet, The, 2021
Alberto M Borobia, Mayte Perez-olmeda, Luis Castaño   +2 more
exaly  

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Lancet, The, 2021
Noam Barda, Noa Dagan, Cyrille J Cohen
exaly  

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Cell, 2021
Stephanie Longet, Donal T Skelly, Wanwisa Dejnirattisai   +2 more
exaly  

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Lancet, The, 2021
Eric J Haas, Msce, David L Swerdlow
exaly  

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Lancet, The, 2021
Sara Y Tartof, Heidi Fischer, Bradley K Ackerson   +2 more
exaly  

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

Lancet, The, 2021
Victoria Hall, Sarah Foulkes, Ayoub Saei
exaly  

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

Lancet, The, 2021
Rajeka Lazarus, Heike Cappel-Porter, Andrew Carson-Stevens   +2 more
exaly